Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.

Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai. The facility will provide analytical and stability services, including analytical method development, transfer and validation for submissions of investigational drug applications and new drug applications for commercial active pharmaceutical ingredients (APIs) and drug product testing; stability studies of APIs, drug products for registration, and commercial products; and reference standard qualification.

Source: WuXi PharmaTech